All AbMole products are for research use only, cannot be used for human consumption.
Ceritinib (LDK378) is a selective small molecule inhibitor of ALK, a target found in metastatic non-small cell lung cancer (NSCLC). Ceritinib (LDK378) shows great anti-proliferative activity in Ba/F3-NPM-ALK and Karpas290 cells with IC50 of 26.0 nM and 22.8 nM, compared with IC50 of 319.5 nM and 2477 nM in Ba/F3-Tel-InsR and Ba/F3-WT cells. LDK378 induces a dose-dependent growth inhibition and tumor regression in the Karpas299 and H2228 rat xenograft models, with no body-weight loss. In Phase I trials, LDK378 showed a marked clinical response in 78 patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer who had progressed during or after crizotinib therapy or had not been previously treated with crizotinib.
Med Oncol. 2022 Dec 28;40(1):64.
FAT4 activation inhibits epithelial-mesenchymal transition (EMT) by promoting autophagy in H2228/Cer cells
LDK378 purchased from AbMole
 |
Source | Oncotarget (2015). Figure 2. LDK378 |
| Method | p.o. | |
| Cell Lines | nude mice | |
| Concentrations | 25 mg/kg | |
| Incubation Time | 21 day | |
| Results | There was a significant inhibition of tumor growth in the group with a combination of ceritinib and paclitaxel compared with other groups (P < 0.05) |
 |
Source | Oncotarget (2015). Figure 1. LDK378 |
| Method | MTT assay | |
| Cell Lines | HEK293/ABCB1 and HEK293/ABCG2-R2 cells | |
| Concentrations | 0.5 μM | |
| Incubation Time | 48 h | |
| Results | Based on the cytotoxicity curves, more than 85% of the cells survived at the concentration of 0.5 μM ceritinib |
| Cell Experiment | |
|---|---|
| Cell lines | Ba/F3-NPM-ALK, Ba/F3-Tel-InsR, Ba/F3-WT, Karpas299 cells |
| Preparation method | Luciferase-expressing cells are incubated with serial dilutions of LDK378 or DMSO for 2-3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software. |
| Concentrations | ~100 μM |
| Incubation time | 2-3 days |
| Animal Experiment | |
|---|---|
| Animal models | RNU nude rats bearing the Karpas299/H2228 tumors |
| Formulation | LDK378 (phosphate salt) formulated in 0.5% methylcellulose/0.5% Tween 80 |
| Dosages | ~50 mg/kg |
| Administration | Oral gavage |
| Molecular Weight | 558.14 |
| Formula | C28H36ClN5O3S |
| CAS Number | 1032900-25-6 |
| Solubility (25°C) | DMSO 10 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related ALK Products |
|---|
| F-1
F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50 values of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively. |
| TL13-22
TL13-22 is a negative control for TL13-12 and a potent ALK inhibitor with an IC50 of 0.54 nM. |
| TL13-110
TL13-110 is a negative control for TL13-112 and a potent ALK inhibitor with an IC50 of 0.34 nM. |
| ALK inhibitor 2
ALK inhibitor 2 is a potent pyrimidin ALK inhibitor. |
| NVL-655 TFA
NVL-655 (ALK-IN-27) TFA is a novel, brain-permeable, selective ALK inhibitor with antitumor activity. For Ba/F3 CLIP1-LTK cells, NVL-655 (ALK-IN-27) TFA has an IC50 of 2.7 nM. It can be used in studies related to ALK-positive non-small cell lung cancer (NSCLC). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
